ASH 2023 | Addition of inotuzumab to alloSCT conditioning regimen in relapsed CD22 (+) lymphoid malignancies
Issa Khouri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the long-term survival outcomes from a study investigating the addition of inotuzumab ozogamicin to a standard chemo-conditioning regimen of bendamustine, fludarabine and rituximab, prior to allogeneic stem cell transplantation (alloSCT). This study enrolled patients with relapsed CD22 (+) lymphoid malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). Although further validation is required in a larger cohort, safety signals were positive, and findings have suggested that this treatment regimen may be associated with improved survival in patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer
